By now it’s well documented that UW-Madison lags behind most of its peers in turning its esteemed research into marketable goods. The question is what would it take for the university to get on track and become a pacesetter in the lucrative development of pharmaceutical drugs and cutting-edge medical treatment? One answer: a “major culture change spearheaded by top leadership.”
That’s the wake-up call sounded in a provocative study commissioned by UW Health and the UW School of Medicine and Public Health. Conducted by consultant Mary Westrick, who has 35 years of experience in clinical testing, the study lays out a series of stark challenges — both organizational as well as attitudinal — that threaten the campus’ declared goal to be a national leader in translating basic research into cutting-edge medical treatment.
Key to success, Westrick argues, is revamping the campus review of research projects that involve human subjects. UW-Madison’s existing clinical trial system, as Westrick and other critics describe it, is a quagmire of red tape that frustrates many campus researchers, while simultaneously failing to embrace standards that produce quality test outcomes.
UW’s existing clinical trials system places way too much emphasis, Westrick says, “on protecting the university from any risk, liability or adverse publicity.” This comes at a cost, she warns: “The result stifles potentially beneficial — even life-saving — research to patients with no counter-balanced benefit of increased patient protection.”
Westrick holds a master’s degree and doctorate in toxicology and pharmacology from Purdue University and has worked in early drug development in the private sector. This includes founding her own 200-employee research lab in Indiana, selling it and then taking an executive post with Covance, a global research operation with a sizable headquarters in Madison. Read the full story here.